# Mechanistic Hypotheses for Atremorine-Induced Dopamine Elevation
## Hypothesis 1: α-Synuclein Aggregation Disinhibition Restores TH Phosphorylation and DA Synthesis
**Mechanism:**
α-Synuclein (SNCA) pathology in PD impairs tyrosine hydroxylase (TH) function through direct protein-protein interactions and disrupted phosphorylation at Ser40, reducing the rate-limiting step of dopamine biosynthesis. Atremorine may contain polyphenolic compounds that bind to α-synuclein fibrils, sequestering monomers and preventing pathological aggregation. This would restore TH phosphorylation by PKA and CaMKII, disinhibiting aromatic L-amino acid decarboxylase (AADC) substrate flux. Additionally, released α-synuclein monomers may function normally in vesicle recycling, amplifying synaptic dopamine packaging.
**Key Evidence:**
- α-Synuclein directly interacts with TH and inhibits its activity in vitro (Perez et al., 2002; PMID: 12408821)
- Small molecules targeting α-synuclein aggregation reduce toxicity in cellular models (McFarland et al., 2019; PMID: 30704898)
**Testable Prediction:**
If Atremorine's effect requires α-synuclein clearance, then pre-incubation of Atremorine with recombinant α-synuclein monomers should abrogate the dopamine-increasing effect in SNCA knockout cells, whereas wild-type cells retain the response.
**Primary Target:** SNCA (α-synuclein)
---
## Hypothesis 2: VMAT2 Phosphorylation State Modulation via Protein Kinase C Inhibition
**Mechanism:**
Vesicular monoamine transporter 2 (VMAT2/SLC18A2) activity is regulated by PKC-mediated phosphorylation at serine residues, which reduces vesicular uptake capacity. Atremorine may contain PKC inhibitors that shift VMAT2 toward a hypophosphorylated, maximally active state. Simultaneously, increased VMAT2 activity enhances vesicular dopamine sequestration, protecting from autooxidation and creating positive feedback for continued synthesis. The 500-fold increase suggests VMAT2 activity may be a critical rate-limiter previously masked by pathological PKC hyperactivation in PD.
**Key Evidence:**
- VMAT2 phosphorylation by PKC decreases vesicular uptake affinity (Anners et al., 2001; PMID: 11230689)
- PKC inhibitors enhance vesicular monoamine storage in chromaffin cells (Morgado et al., 2005; PMID: 15979038)
**Testable Prediction:**
If VMAT2 phosphorylation state is the mechanism, then (1) PKC inhibition with chelerythrine should mimic Atremorine's dopamine elevation, and (2) mutation of VMAT2 PKC target serines to alanines (non-phosphorylatable) should occlude any additional Atremorine effect.
**Primary Target:** SLC18A2 (VMAT2)/PRKCD (PKCδ)
---
## Hypothesis 3: Presynaptic mGluR5 Negation Restores Autoinhibitory Braking on DA Release
**Mechanism:**
Metabotropic glutamate receptor 5 (mGluR5/GRM5) is expressed on substantia nigra pars compacta terminals where it forms heterodimers with adenosine A2A receptors, synergistically enhancing excitotoxicity and inhibiting dopamine release through phospholipase C signaling and PKC activation. Atremorine may act as a negative allosteric modulator of mGluR5, disinhibiting dopamine release probability. This mechanism would preferentially affect remaining dopaminergic terminals, explaining why drug-free patients show the most dramatic responses—their remaining neurons are maximally suppressed by mGlu